19 completed, 12 unknown, 7 active not recruiting, 5 recruiting. 17 Phase 2, 9 Phase 1, 3 Not applicable, 2 Phase 3.
Follow Microsatellite Instability: new trials by email Literature Review of Microsatellite Instability trials Research Report on Microsatellite Instability
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo - Colorectal Cancer | Phase 3 | Recruiting | Exelixis | 600 | 2026-12-18 | 2026-11-12 |
| Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study. Pembrolizumab Injection [Keytruda], Watch-and-wait approach, Surgery - Colon Cancer | Phase 2 | Not yet recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 60 | 2025-09-01 | 2025-06-13 |
| A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. NDI-219216 - Advanced Solid Tumors Cancer, MSI-H Cancer | Phase 1 / Phase 2 | Recruiting | Nimbus Wadjet, Inc. | 134 | 2025-03-31 | 2026-05-06 |
| First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers ATX-559 - Advanced Solid Tumors, Breast Cancer Recurrent | Phase 1 | Terminated | Accent Therapeutics | 17 | 2024-10-11 | 2026-02-24 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors VVD-133214, Pembrolizumab, Bevacizumab - Advanced Solid Tumors, Colorectal Cancer | Phase 1 | Recruiting | Vividion Therapeutics, Inc. | 280 | 2024-01-25 | 2026-11-12 |
| MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas DC vaccine - Glioma | Unknown | Huashan Hospital | 360 | 2023-09-01 | 2023-09-21 | |
| Liquid Biopsy Biomarkers for Endoscopic Surveillance in Lynch Syndrome Study procedures - Lynch Syndrome, Hereditary Nonpolyposis Colorectal Cancer | Completed | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 109 | 2023-06-20 | 2026-09-24 | |
| Non-Invasive Diagnosis of Endometrial Cancer cervical cytology during surgery. - Endometrial Cancer | Not applicable | Unknown | Assistance Publique - Hôpitaux de Paris | 100 | 2023-03-03 | 2024-02-22 |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) - Advanced Solid Tumors, Genital Neoplasm, Female | Phase 1 / Phase 2 | Recruiting | Marengo Therapeutics, Inc. | 366 | 2023-01-04 | 2026-08-11 |
| Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy Colorectal Cancer, Colorectal Cancer Metastatic | Completed | OncoAtlas LLC | 30 | 2022-06-01 | 2025-06-27 | |
| Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer Prolgolimab - Colorectal Cancer | Phase 2 | Completed | Blokhin's Russian Cancer Research Center | 30 | 2022-03-31 | 2026-04-27 |
| Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) Capecitabine, Oxaliplatin, Retifanlimab - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 25 | 2021-11-05 | 2024-08-02 |
| Microsatellite Instability in Colorectal Cancers Microsatellite instability analysis - Colorectal Cancer, Colorectal Carcinoma | Completed | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | 231 | 2021-04-01 | 2021-12-17 | |
| TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. Durvalumab, Tremelimumab - Gastric Cancer, Microsatellite Instability | Phase 2 | Active not recruiting | Gruppo Oncologico del Nord-Ovest | 31 | 2021-04-01 | 2026-09-11 |
| Genetic Mutation in Recurrent Cervical Cancer Multi-gene panel testing - Recurrent Cervical Cancer, Nucleotide Variant | Unknown | Lei Li | 300 | 2019-12-19 | 2019-12-20 | |
| Genetic Mutation in Epithelial Ovarian Cancer A multi-gene panel testing - Epithelial Ovarian Cancer, Nucleotide Variant | Unknown | Lei Li | 500 | 2019-12-19 | 2019-12-20 | |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers Tumor Infiltrating Lymphocytes (TIL), Fludarabine + Cyclophosphamide combination - Gastric Cancer, Colorectal Cancer | Phase 2 | Active not recruiting | Udai Kammula | 20 | 2019-12-03 | 2026-06-01 |
| Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. Nivolumab 10 MG/ML, Ipilimumab 200 MG in 40 ML Injection - Localized Oesogastric Adenocarcimona, MSI and or dMMR | Phase 2 | Active not recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 32 | 2019-10-23 | 2025-06-15 |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy Allogeneic natural killer (NK) cell - Advanced Solid Tumor, Lymphoma | Terminated | Fate Therapeutics | 20 | 2019-06-11 | 2023-09-21 | |
| Frequency of Endometrial Cancer Precursors Associated with Lynch Syndrome Immunohistochemical staining - Lynch Syndrome, Endometrial Cancer | Completed | WellSpan Health | 91 | 2019-05-08 | 2025-03-28 |
Showing 20 of 49. Sign in to see all of them.
Colorectal Neoplasms (24) · Stomach Neoplasms (10) · Endometrial Neoplasms (7) · Turcot syndrome (7) · Uterine Cervical Neoplasms (7) · Carcinoma, Merkel Cell (6) · Carcinoma, Renal Cell (6) · Colonic Neoplasms (6) · Melanoma (6) · Small Cell Lung Carcinoma (6) · Carcinoma, Hepatocellular (5) · Colorectal Neoplasms, Hereditary Nonpolyposis (5) · Head and Neck Neoplasms (5) · Carcinoma, Transitional Cell (4)
Genomic Instability (49) · Pathologic Processes (49) · Pathological Conditions, Signs and Symptoms (49) · Neoplasms (42) · Neoplasms by Site (41) · Digestive System Diseases (37) · Digestive System Neoplasms (37) · Gastrointestinal Diseases (37) · Gastrointestinal Neoplasms (36) · Intestinal Diseases (32) · Intestinal Neoplasms (32) · Colonic Diseases (31) · Rectal Diseases (26) · Genital Diseases (15) · Urogenital Diseases (15)
pembrolizumab (8) · Nivolumab (6) · durvalumab (3) · Cyclophosphamide (2) · Docetaxel (2) · Injections (2) · Ipilimumab (2) · atezolizumab (2) · avelumab (2) · fludarabine (2) · ALT-803 (1) · Bevacizumab (1) · Capecitabine (1) · Carboxylesterase (1) · Chemotherapy, Adjuvant (1)
GERCOR - Multidisciplinary Oncology Cooperative Group (3) · Lei Li (3) · Assistance Publique - Hôpitaux de Paris (2) · Fate Therapeutics (2) · National Taiwan University Hospital (2) · Radboud University Medical Center (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Accent Therapeutics (1) · Affiliated Hospital of Qinghai University (1) · Apollomics (Australia) Pty. Ltd. (1) · Blokhin's Russian Cancer Research Center (1) · Exelixis (1) · Federation Francophone de Cancerologie Digestive (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Gruppo Oncologico del Nord-Ovest (1)
United States (16) · France (11) · China (9) · Australia (3) · Canada (3) · Italy (3) · Netherlands (3) · Spain (3) · United Kingdom (3) · Russia (2) · Taiwan (2) · Belgium (1) · Denmark (1) · Ireland (1) · Malaysia (1)
Jin-Tung Liang, M.D., Ph.D. (2) · Lei Li, M.D. (2) · Anita Scheuber, MD, PhD (1) · Bernard Hirschel (1) · David Tougeron, MD PHD (1) · Dung Le, MD (1) · Eav Lim, DO (1) · Filippo Pietrantonio, MD (1) · Hanneke WM van Laarhoven, MD, PhD (1)
PMID 20379742, PMID 30943124, PMID 31682550, PMID 31980466, PMID 32079623, PMID 32359091, PMID 32919526, PMID 33109741, PMID 33148693, PMID 33836153, PMID 33992635, PMID 34990208, PMID 35114169, PMID 35361487, PMID 35522273, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35791694, PMID 35835611, PMID 35969830, PMID 36748723, PMID 37269904, PMID 39594133, PMID 39637944, PMID 39979665, PMID 40121391, PMID 40340830, PMID 40389373, PMID 41370727, PMID 41920388, PMID 42811189
2023 (2), 2015 (1), 2016 (1), 2018 (1), P30CA014089 (1), P30CA015704 (1), P50CA062924 (1)